- 4009 Hackney Springs Ln, Sachse, TX 75048
Definitive drug testing billing separates two coding paths for the same LC-MS/MS confirmation test. The American Medical Association’s CPT codes, 80320 through 80377, organize billing by individual drug class, and most commercial payers accept them. Medicare and many Medicare Advantage plans require HCPCS G-codes instead, G0480 through G0483 plus G0659, which group testing by the total number of drug classes confirmed instead of naming each one. Billing CPT codes to Medicare results in an automatic denial, since Medicare considers that range as non-reimbursable for definitive testing.
Getting paid correctly depends on matching the code set to the payer, documenting medical necessity for each test ordered, staying within frequency limits set by local coverage determinations, and applying modifiers correctly when specimen validity testing is billed alongside the panel. Labs that build payer-specific rules into their claims process, or partner with billing specialists, see fewer denials and faster reimbursement.
Every lab that runs LC-MS/MS confirmation panels for pain management, addiction treatment, or primary care referrals knows one thing for certain. Definitive drug testing billing is one of the most confusing parts of laboratory revenue cycle management. One payer wants a CPT code. Another wants a G-code. If you get it wrong, the claim comes back denied, or worse, it gets flagged for a payer audit.
Laboratories that use professional urological testing billing services stay ahead of it. Using these services helps labs sort out drug class selection, code assignment, and claim submission for definitive testing performed in urology, pain management, and primary care settings, so revenue doesn’t get stuck in appeals.
Want to know how to use the right billing and coding for definitive drug testing to get claims reimbursed? Let’s discuss.
Definitive drug testing billing is the process of coding, documenting, and submitting claims for laboratory tests that identify and measure the exact drugs and metabolites present in a patient’s sample. Unlike a quick screening test, definitive testing uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) to confirm results with accuracy that supports clinical decisions.
Physicians order it when they need to know precisely which substances a patient has taken, at what concentration, and whether a presumptive result needs confirmation. Because the testing itself is complex, the billing side is just as detailed. Labs have to match the right code series to the right payer, document medical necessity, and follow frequency rules that vary from one plan to the next.
Before we get into codes, it helps to separate the two types of drug testing.
Presumptive testing is a fast screen, usually done with an immunoassay, that gives a positive or negative result for a class of drugs. It’s billed under CPT 80305–80307, and only one of these three codes can be reported per day, no matter how many drug classes were screened.
Definitive testing is different. It identifies specific drugs and metabolites, confirms unexpected presumptive results, and supports ongoing medication monitoring. This is where urine drug testing moves from a screening tool to a diagnostic one, and it’s also where drug testing confirmation billing starts to get complicated, because two separate code sets exist for the same clinical service.
These tests don’t have just one code. The American Medical Association (AMA) maintains definitive drug testing CPT codes 80320 through 80377. These codes are organized by drug class, so a lab reports a separate code for each class confirmed, such as opiates, benzodiazepines, or stimulants.
Codes 80375 through 80377 cover drug classes that don’t fit anywhere else in the list, and CPT guidance reserves them for less common substances.
Now, when you look at it, coding looks very simple. A lab runs a panel, counts the drug classes confirmed, and bills the matching codes. However, it’s not that easy. Commercial payers generally accept this CPT range, but Medicare does not. Now, this confuses labs as to how to bill claims to Medicare, which we’ll cover in the next section.
Medicare doesn’t use the CPT range at all for definitive testing. Instead, it created its own HCPCS G-codes for definitive drug testing, built around the total number of drug classes tested, as mentioned in the CMS Billing & Coding Article A54799, titled “Urine Drug Testing”. Only one G-code can be billed per date of service, regardless of how many individual drugs were confirmed within that class count. These codes also carry a higher testing standard than the CPT equivalents, requiring stable isotope or internal standard calibration and method-specific quality controls consistent with high-complexity mass spectrometry.
| G-Code | Drug Classes Covered | Notes |
|---|---|---|
| G0480 | 1 to 7 drug classes | Most common code for smaller definitive panels |
| G0481 | 8 to 14 drug classes | Mid-size definitive panels |
| G0482 | 15 to 21 drug classes | Larger definitive panels |
| G0483 | 22 or more drug classes | Extensive definitive panels |
| G0659 | Certain single drug class testing | Applies under specific payer policy |
| Feature | CPT 80320–80377 | HCPCS G0480–G0483 / G0659 |
|---|---|---|
| Issued by | American Medical Association | Centers for Medicare & Medicaid Services |
| Billing structure | One code per drug class confirmed | One code per date of service, based on total class count |
| Accepted by Medicare | No, treated as non-reimbursable | Yes, required |
| Accepted by commercial payers | Often, per contract | Sometimes, per contract or plan policy |
Medicare and most Medicare Advantage plans require the G-code set and will deny CPT 80320-80377 claims outright, deeming them invalid for reimbursement. Many commercial payers and some state Medicaid programs go the other direction and expect the CPT codes instead. A handful of plans accept either, but only if the lab’s contract or local coverage determination specifically allows it.
Labs that bill both Medicare and commercial patients for the same LC-MS/MS drug testing billing process need two different coding pathways for functionally the same test. If labs don’t follow that, billing errors occur and result in claim denials.
But the reassuring news is that it’s all preventable. All you have to do is outsource lab billing and coding services to a partner, like TransLabs, who keeps up with G-code updates and payer coding rules. When you hand over the billing to these specialists, they track policy changes, apply the right codes, and catch documentation gaps on your behalf before submitting the claims. This reduces denials and speeds up reimbursement, while freeing up your lab to get paid right.
Medicare coverage and billing rules for definitive testing are set through national guidance and local coverage determinations issued by each Medicare Administrative Contractor. Coverage depends on documented medical necessity, not just a standing order. The medical record needs to show the reason for definitive testing, whether that’s:
Medicare drug testing reimbursement is also capped by frequency limits that vary by LCD, and testing beyond those limits without documented justification is a common reason claims get downcoded or denied. Because Medicare doesn’t describe CPT 80320-80377 as reimbursable for this service, any claim submitted on those codes to a MAC is denied before it even reaches medical review, despite proper and complete documentation.
Reviewers and auditors look for:
Labs should keep this documentation on file and ready to produce, since definitive drug testing is one of the more frequently audited services in laboratory billing. Vague documentation that relies on a general standing order to justify every test is a high-risk red flag that can quickly get your lab selected for a Targeted Probe and Educate review by Medicare.
So, make sure to use a specific standing order for this test with correct documentation to justify necessity, and qualify the claim for reimbursement.
Specimen validity testing, such as creatinine, pH, and specific gravity checks, confirms that a urine sample wasn’t diluted, substituted, or adulterated. Most payers consider these checks bundled into the drug testing panel and won’t reimburse them as separate line items.
When a lab does need to report a distinct procedural service on the same date, modifier 59 or the more specific X-modifiers can separate services that would otherwise be bundled under National Correct Coding Initiative edits.
Modifier 91 applies when a repeat definitive test is medically necessary on the same day, not simply a repeat of the same result. Applying these modifiers without solid documentation to back them up is a common audit trigger, so you should only use them when the medical record clearly supports a distinct, separately identifiable service.
Traditional Medicare mostly doesn’t require prior authorization for medically necessary definitive testing. But many commercial payers and Medicaid managed care organizations require prior authorization once a panel exceeds a certain number of drug classes, or when testing frequency exceeds what the plan considers routine for a patient’s treatment setting.
This is especially common in pain management and substance use disorder programs, where high-frequency testing draws closer scrutiny. Before running a large LC-MS/MS panel, it’s important to check the specific payer’s policy, since submitting a claim without required authorization can lead to a denial.
A clean claim for definitive urine drug testing generally follows the same sequence:
All that helps with a smooth claim submission process and quicker reimbursement for every lab claim.
Definitive drug testing billing comes down to one core decision: which code set the payer wants. Medicare requires HCPCS G-codes, while many commercial payers still accept CPT codes 80320 through 80377. Getting this wrong is the single biggest cause of denial for definitive testing claims.
Labs that verify payer type before coding, document medical necessity for every test, and track frequency limits see fewer denials. When billing complexity grows, working with experienced lab billing specialists protects revenue and keeps claims moving.